immunology

Sanofi Cuts a Whopping 38 R&D Programs to Refocus on Cancer, Immunology, and Rare Diseases
Sanofi Cuts a Whopping 38 R&D Programs to Refocus on Cancer, Immunology, and Rare Diseases
BioSpace
Sanofi
Rare Diseases
immunology
cancer
R&D
Flag link:
J&J still sees plenty of opportunity in crowded immunology markets—starting with psoriasis
J&J still sees plenty of opportunity in crowded immunology markets—starting with psoriasis
Fierce Pharma
JNJ
JPMHC 2019
immunology
psoriasis
Tremfya
Flag link:
Forget Remicade -- Here's How Johnson & Johnson Plans to Grow
Forget Remicade -- Here's How Johnson & Johnson Plans to Grow
Motley Fool
JNJ
Stelara
Zytiga
Darzalex
oncology
immunology
Flag link:
ABBV to Focus on Advancing Late-Stage Immunology Research in 2018
ABBV to Focus on Advancing Late-Stage Immunology Research in 2018
Market Realist
AbbVie
R&D
immunology
Upadacitinib
risankizumab
Flag link:
Eli Lilly, sporting a lower tax rate, scouts smaller deals in immunology, cancer
Eli Lilly, sporting a lower tax rate, scouts smaller deals in immunology, cancer
Fierce Pharma
Eli Lilly
M&A
immunology
Flag link:
Charles River buys KWS BioTest for $20M, gaining immunology discovery capacity and a UK footprint
Charles River buys KWS BioTest for $20M, gaining immunology discovery capacity and a UK footprint
Endpoints
Charles River Laboratories
KWS BioTest
M&A
immunology
R&D
Flag link:
King cancer: The top 10 therapeutic areas in biopharma R&D
King cancer: The top 10 therapeutic areas in biopharma R&D
Endpoints
R&D
cancer
neurology
infection
immunology
cardiovascular disease
diabetes
Flag link:
U.S. prosecutors zero in on J&J marketing, targeting top immunology, hep C meds
U.S. prosecutors zero in on J&J marketing, targeting top immunology, hep C meds
Fierce Pharma
JNJ
drug manufacturing
immunology
hepatitis C
Remicade
Simponi
Stelara
Olysio
Flag link:
Immunology Among Areas to Watch as Johnson & Johnson Gears Up to Report Results
Immunology Among Areas to Watch as Johnson & Johnson Gears Up to Report Results
TheStreet.com
JNJ
earnings
immunology
diabetes
Flag link:
Bristol-Myers Squibb Enters Collaboration to Leverage Foundation Medicine’s Molecular Information Platform to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy Agents
Bristol-Myers Squibb Enters Collaboration to Leverage Foundation Medicine’s Molecular Information Platform to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy Agents
Yahoo
Bristol-Myers Squibb
Foundation Medicine
R&D
tumors
immunology
Flag link:
Johnson & Johnson's Immunology Pipeline Is Golden
Johnson & Johnson's Immunology Pipeline Is Golden
Seeking Alpha
JNJ
immunology
Stelara
sirukumab
CNTO 6785
Flag link: